Lung and gut microbiomes in pulmonary aspergillosis: Exploring adjunctive therapies to combat the disease

Liuyang Cai; Liuyang Cai; Peigen Gao; Peigen Gao; Zeyu Wang; Zeyu Wang; Chenyang Dai; Chenyang Dai; Ye Ning; Ye Ning; Macit Ilkit; Xiaochun Xue; Jinzhou Xiao; Chang Chen; Chang Chen

doi:10.3389/fimmu.2022.988708

Frontiers in Immunology (Aug 2022)

Lung and gut microbiomes in pulmonary aspergillosis: Exploring adjunctive therapies to combat the disease

Liuyang Cai,
Liuyang Cai,
Peigen Gao,
Peigen Gao,
Zeyu Wang,
Zeyu Wang,
Chenyang Dai,
Chenyang Dai,
Ye Ning,
Ye Ning,
Macit Ilkit,
Xiaochun Xue,
Jinzhou Xiao,
Chang Chen,
Chang Chen

Affiliations

Liuyang Cai: Shanghai Engineering Research Center of Lung Transplantation, Shanghai, China
Liuyang Cai: Basic School of Medicine, Second Military Medical University (Naval Medical University), Shanghai, China
Peigen Gao: Shanghai Engineering Research Center of Lung Transplantation, Shanghai, China
Peigen Gao: Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
Zeyu Wang: Shanghai Engineering Research Center of Lung Transplantation, Shanghai, China
Zeyu Wang: Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
Chenyang Dai: Shanghai Engineering Research Center of Lung Transplantation, Shanghai, China
Chenyang Dai: Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
Ye Ning: Shanghai Engineering Research Center of Lung Transplantation, Shanghai, China
Ye Ning: Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
Macit Ilkit: Division of Mycology, Department of Microbiology, Faculty of Medicine, University of Çukurova, Adana, Turkey
Xiaochun Xue: Department of Pharmacy, 905th Hospital of People’s Liberation Army of China (PLA) Navy, Shanghai, China
Jinzhou Xiao: Shanghai Engineering Research Center of Hadal Science and Technology, College of Marine Sciences, Shanghai Ocean University, Shanghai, China
Chang Chen: Shanghai Engineering Research Center of Lung Transplantation, Shanghai, China
Chang Chen: Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China

DOI: https://doi.org/10.3389/fimmu.2022.988708
Journal volume & issue: Vol. 13

Abstract

Read online

Species within the Aspergillus spp. cause a wide range of infections in humans, including invasive pulmonary aspergillosis, chronic pulmonary aspergillosis, and allergic bronchopulmonary aspergillosis, and are associated with high mortality rates. The incidence of pulmonary aspergillosis (PA) is on the rise, and the emergence of triazole-resistant Aspergillus spp. isolates, especially Aspergillus fumigatus, limits the efficacy of mold-active triazoles. Therefore, host-directed and novel adjunctive therapies are required to more effectively combat PA. In this review, we focus on PA from a microbiome perspective. We provide a general overview of the effects of the lung and gut microbiomes on the growth of Aspergillus spp. and host immunity. We highlight the potential of the microbiome as a therapeutic target for PA.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords